口服胰岛素上市申请未能成功

Core Viewpoint - The application for the oral insulin capsule by Hefei Tianhui Biotechnology Co., Ltd. has not been successful, raising concerns about the future of this innovative product in the diabetes treatment market [1][3]. Group 1: Product Overview - The recombinant human insulin enteric-coated capsule is notable for being the first oral insulin product to apply for listing globally, aimed at treating type 2 diabetes patients who do not respond well to oral hypoglycemic agents [1]. - This product is an introduced product from the Israeli company Oramed, which has faced challenges in its clinical trials [1][3]. Group 2: Clinical Trial Challenges - The development of oral insulin is complex due to the nature of insulin as a protein hormone, which is large in molecular weight and susceptible to enzymatic degradation [3]. - Oramed's previous phase III clinical trials for the oral insulin capsule ORM-D-0801 did not meet primary and secondary endpoints, leading to skepticism about the product's viability [3]. Group 3: Market Implications - The failure of the listing application for the oral insulin capsule may impact Tianhui Biotechnology's future investments and strategies in the diabetes treatment sector [3].